Rizatriptan

Rizatriptan
Klinički podaci
Prodajno ime	Maxalt, Maxalt MLT, Maxalt-MLT
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	2-3 h
Identifikatori
CAS broj	145202-66-0
ATC kod	N02CC04 (WHO)
PubChem	CID 5078
IUPHAR/BPS	51
DrugBank	DB00953
ChemSpider	4900
ChEBI	CHEBI:48273
ChEMBL	CHEMBL905
Hemijski podaci
Formula	C15H19N5
Molarna masa	269,345
	SMILES CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2; ;
	InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 ; Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	178—180 °C (352—356 °F)

Rizatriptan je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 269,345 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine[уреди | уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	5
Particioni koeficijent^[8] (ALogP)	2,1
Rastvorljivost^[9] (logS, log(mol/L))	-3,7
Polarna površina^[10] (PSA, Å²)	49,7

Reference[уреди | уреди извор]

^ Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. PMID 12093318
^ Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. PMID 12269863
^ Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance] Nippon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. PMID 15056946
^ Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. PMID 12434581
^ Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. PMID 11152011
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди